<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36074738</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>36</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder - Chongqing, China, 2022.</ArticleTitle><Pagination><StartPage>1148</StartPage><EndPage>1150</EndPage><MedlinePgn>1148-1150</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7136a2</ELocationID><Abstract><AbstractText>Oral poliovirus vaccine (OPV) has proven to be highly effective in the global effort to eradicate poliomyelitis because of its ability to induce both humoral and intestinal immunity, ease of administration, and low cost (1). Sabin-strain OPV contains live attenuated virus and induces immunity by replicating in the intestinal tract, triggering an immune response that clears the vaccine virus. However, among undervaccinated communities and persons with immunodeficiency, OPV mutations that arise during prolonged replication can result in the emergence of genetically divergent, neurovirulent vaccine-derived polioviruses (VDPVs). In addition, OPV has resulted in rare cases of vaccine-associated paralytic poliomyelitis (VAPP) among vaccine recipients or their close contacts (1). Identification of circulating polioviruses relies on surveillance of acute flaccid paralysis (AFP) and environmental surveillance of wastewater (i.e., sewage). In 2022, type 3 VDPV (VDPV3) was detected in stool specimens from an infant with primary immunodeficiency disorder (PID) through a pilot surveillance program to identify VDPVs in children with PIDs. Integrated AFP, environmental, and immunodeficiency-associated VDPV (iVDPV) surveillance is critical to detecting and containing all polioviruses and achieving the goal of global polio eradication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ning</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jia-Wei</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zun-Dong</ForeName><Initials>ZD</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Ning</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rodewald</LastName><ForeName>Lance E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhi-Yong</ForeName><Initials>ZY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="Y">Immunologic Deficiency Syndromes</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081207" MajorTopicYN="Y">Primary Immunodeficiency Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36074738</ArticleId><ArticleId IdType="pmc">PMC9470223</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7136a2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang HB, Luo HM, Li L, et al. Vaccine-derived poliovirus surveillance in China during 2001&#x2013;2013: the potential challenge for maintaining polio free status. BMC Infect Dis 2017;17:742&#x2013;9. 10.1186/s12879-017-2849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2849-z</ArticleId><ArticleId IdType="pmc">PMC5712118</ArticleId><ArticleId IdType="pubmed">29197328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Wilkinson AL, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF. Progress toward polio eradication&#x2014;worldwide, January 2019&#x2013;June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1129&#x2013;35. 10.15585/mmwr.mm7034a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7034a1</ArticleId><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pethani AS, Kazi Z, Nayyar U, et al. Poliovirus excretion among children with primary immune deficiency in Pakistan: a pilot surveillance study protocol. BMJ Open 2021;11:e045904. 10.1136/bmjopen-2020-045904</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045904</ArticleId><ArticleId IdType="pmc">PMC8319991</ArticleId><ArticleId IdType="pubmed">34321293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine 2018;36:1711&#x2013;9. 10.1016/j.vaccine.2018.02.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.059</ArticleId><ArticleId IdType="pubmed">29478755</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio laboratory manual. 4th ed. Geneva, Switzerland: World Health Organization; 2004. https://apps.who.int/iris/bitstream/handle/10665/68762/WHO_IVB_04.10.pdf?sequence=1&amp;isAllowed=y</Citation></Reference><Reference><Citation>Macklin G, Diop OM, Humayun A, et al. Update on immunodeficiency-associated vaccine-derived polioviruses&#x2014;worldwide, July 2018&#x2013;December 2019. MMWR Morb Mortal Wkly Rep 2020;69:913&#x2013;7. 10.15585/mmwr.mm6928a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty MC, Madkaikar MR, Desai M, et al. Poliovirus excretion in children with primary immunodeficiency disorders, India. Emerg Infect Dis 2017;23:1664&#x2013;70. 10.3201/eid2310.170724</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2310.170724</ArticleId><ArticleId IdType="pmc">PMC5621533</ArticleId><ArticleId IdType="pubmed">28930011</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos A, Dias A, Cordeiro A, et al. Severe axillary lymphadenitis after BCG vaccination: alert for primary immunodeficiencies. J Microbiol Immunol Infect 2010;43:530&#x2013;7. 10.1016/S1684-1182(10)60082-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1684-1182(10)60082-5</ArticleId><ArticleId IdType="pubmed">21195982</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol 2014;133:1134&#x2013;41. 10.1016/j.jaci.2014.02.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.02.028</ArticleId><ArticleId IdType="pmc">PMC4015464</ArticleId><ArticleId IdType="pubmed">24679470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Modlin JF, Zaffran M. Completing polio eradication: the case for antiviral drugs. J Infect Dis 2017;215:333&#x2013;4. 10.1093/infdis/jiw547</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw547</ArticleId><ArticleId IdType="pubmed">27932609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>